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Certain drugs that interfere with folate metabolism (sulfones, sulfonamides, and inhibitors of dihydrofolate
reductase) play an important role in the chemotherapy and prophylaxis of malaria. The activities and
mechanisms of action of these drugs are regarded as similar in most respects to their activities against
procaryotic microorganisms. Believed incapable of utilizing intact exogenous folates, plasmodia have been
regarded as dependent on de novo synthesis of required folate cofactors. The present investigation, conducted
in pursuit of a method for testing the in vitro susceptibility of Plasmodium falciparum to antifol antimalarial
drugs, produced evidence that earlier assumptions about the folate metabolism of this organism are not correct.
Three of four isolates of P. falciparum were successfully maintained in a culture medium depleted of folic acid
and p-aminobenzoic acid. The antimalarial activities of sulfonamides and dihydrofolate reductase inhibitors
were, furthermore, variably antagonized by the presence of folic acid and p-aminobenzoic acid in the culture
medium. Optimum conditions for assessment of antifol antimalarial activity in vitro therefore require precise
control of these factors in the culture medium. Our results suggest that resistance to antifol antimalarial drugs
involves a complex of factors related to both the de novo synthesis of active folate cofactors and the ability to
utilize exogenous intact folates in various forms.
The antimalarial activity of therapeutic agents that inter-
fere with folate (FA) metabolism has long been recognized
(5, 10). Two categories of antifol antimalarial drugs are
distinguished by their respective mechanisms of action. In
the first category, the sulfonamides and sulfones are chem-
ical analog of p-aminobenzoic acid (PABA), an essential
precursor for the de novo synthesis of FA. The second
category includes a variety of drugs that inhibit dihydrofol-
ate reductase (DHFR), the enzyme responsible for convert-
ing dihydrofolate to the biologically active tetrahydrofolate
cofactor.
Competitive antagonism by PABA of the activity of sul-
fonamides has been demonstrated in vivo with Plasmodium
gallinaceum (14) and Plasmodium berghei (20) and in vitro
with Plasmodium knowlesi (15) and Plasmodium falciparum
(18). Furthermore, plasmodia have been regarded as similar
to procaryotic organisms in their inability to utilize intact
exogenous FAs (7). Because malaria parasites also do not
incorporate exogenous thymine or thymidine, the thymidyl-
ate required for DNA synthesis must be synthesized de novo
in a process requiring an active tetrahydrofolate cofactor. It
follows that plasmodia either synthesize de novo or depend
for their survival on an exogenous source of PABA (11).
Reversal of the activity of sulfonamides and DHFR inhib-
itors by FA has been reported with P. gallinaceum in vivo
(17) and P. knowlesi in vitro (15). It has been attributed
possibly to breakdown of the intact molecule and utilization
of the (p-aminobenzoyl)glutamate (PABG) or to contamina-
tion of the FA used in those studies (7). The in vitro activity
of DHFR inhibitors against resistant isolates and of sulfon-
amides against all isolates of P. falciparum could not be
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demonstrated in an FA- and PABA-enriched culture medium
(RPMI 1640) at achievable concentrations of the drugs (1, 4).
Our studies were undertaken to evaluate the factors affecting
the activity of antifol antimalarial drugs in vitro.
MATERIALS AND METHODS
Cultivation of parasites. We used four isolates of P.
falciparum in these studies. The Sierra Leone I/CDC, Indo-
china I/CDC, and Indochina III/CDC isolates were obtained
from the Malaria Branch, Division of Parasitic Diseases,
Centers for Disease Control, Atlanta, Ga. The Liberia I/UNC
isolate was obtained from a patient in North Carolina who
developed falciparum malaria after a visit to Liberia. These
isolates were maintained in vitro by modification of the
methods of Trager and Jensen (21) and Haynes et al. (9).
Sealed 50-ml culture flasks (Coming Glass Works, Corning,
N.Y.) were filled with 5 ml of culture medium supplemented
with 10% fresh frozen human plasma and type A+ human
erythrocytes at a hematocrit of 6%. The parasite density was
maintained below 2% under an atmosphere of 5% C02, 5%
02, and 90% N2 at 37°C. The culture media consisted of
standard RPMI 1640 or special FA- and PABA-free RPMI
1640 (GIBCO Laboratories, Grand Island, N.Y.) with 32 mM
NaHCO3 (GIBCO) and 25 mM HEPES (N-2-hydroxyeth-
ylpiperazine-N'-2-ethanesulfonic acid; Calbiochem-Behring,
La Jolla, Calif.) buffer. Fresh frozen human plasma and
erythrocytes were obtained in acid-citrate-dextrose anti-
coagulant from the U.S. Army Blood Donor Center, Fort
Bragg, N.C.
Preparation of dialyzed human plasma. Normal human
plasma contains 6 to 20 ng of FA per ml (24), most of which
is nonspecifically protein bound and freely dialyzable (16).
The PABA concentration of normal human plasma varies
greatly but is generally less than 1.0 ng/ml (R. Desjardins,
unpublished observations). Therefore, to evaluate quantita-
tively the effects of these constituents on the antimalarial
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activities of the antifol drugs, it was necessary to dialyze the
plasma used to supplement the culture medium. Heat-inac-
tivated plasma was dialyzed in sterile cellulose dialysis bags
at 4°C (Spectra-Por 12-140000 MWCO; Fisher Scientific Co.,
Silver Spring, Md.) for 72 h with a 10:1 volume of dialysate
consisting of normal saline which was changed twice daily.
The FA and PABA concentrations of dialyzed plasma were,
respectively, 1.7 ng/ml and nondetectable by a sensitive
microbiological assay (limit, 0.04 ng/ml).
Assessment of parasite growth under different medium
conditions. Growth of the four isolates during continuous
culture was assessed periodically in the following media: (i)
standard RPMI 1640 medium (which contains 1.0 ,ug of FA
per ml and 1.0 ,ug of PABA per ml) supplemented with 10%
nondialyzed human plasma (normal medium with normal
plasma); (ii) standard RPMI 1640 medium supplemented
with 10% dialyzed human plasma (normal medium with
dialyzed plasma); (iii) FA- and PABA-free RPMI 1640 me-
dium supplemented with 10% nondialyzed human plasma
(deficient medium with normal plasma); (iv) FA- and PABA-
free RPMI 1640 medium supplemented with 10% dialyzed
human plasma (deficient mediumn with dialyzed plasma).
The growth rates (R) in each case were evaluated logarith-
mically according to the following calculation:
logistic-logarithmic function permits the use of Xi = 0 and
direct estimation of anyf(i.e.,f = 0.5 for 50% IC [1IC50],f=
0.9 for 90% IC [IC90], etc.).
Determinations of the IC50 were made for all of the
available sulfonamides, sulfones, and DHFR inhibitors in
deficient medium with dialyzed plasma. The optimum dura-
tion of in vitro exposure to sulfonamide (sulfamethoxazole)
before labeling with [G-3H]hypoxanthine was determined by
comparing the concentration-response curves at 24, 40, 48,
and 64 h.
Antagonism of antifol activity. To explore the effects of
FA, PABA, and PABG on the in vitro activity of a sulfon-
amide (sulfadoxine) and a DHFR inhibitor (pyrimethamine),
the approximate IC90s of these drugs were estimated for a
sensitive (Liberia I/UNC) and a resistant (Indochina I/CDC)
isolate. A similar determination was made with sulfadoxine
for an isolate with intermediate susceptibility (Sierra Leone
I/CDC). The uptake of [G-3H]hypoxanthine by each isolate
in deficient medium in with dialyzed plasma at the approxi-
mate IC90s of the drugs was determined with the addition of
FA, PABA, or PABG at 10-fold serial dilutions of 10-5 to
10-9 M. Simultaneous control cultures without the addition
of pyrimethamine or sulfadoxine were evaluated at 10-5,
10-7, and 10-9 M concentrations of FA, PABA, and PABG.
R In A2 - ln Al
Td
(1)
where ln A1 and ln A2 are the natural logarithm of the number
of parasites observed at time one (t1) and time two (t2),
respectively, and the duration Td = t2 - tl.
A separate measure of parasite growth rate was provided
by the observed uptake of [G-3H]hypoxanthine (New Eng-
land Nuclear Corp., Boston, Mass.) during a 68-h incubation
of one of the isolates (Liberia I/UNC) in the four different
culture media. The effects of FA and PABA on the growth
rate of the one isolate (Sierra Leone I/CDC) which did not
survive in the deficient medium with dialyzed plasma was
also evaluated by the uptake of [G-3H]hypoxanthine.
Antimalarial activities of antifols. The drugs and chemicals
used in these studies were obtained as gifts or were pur-
chased from Burroughs Wellcome Co., Research Triangle
Park, N.C. (sulfamethoxazole, PABG, pyrimethamine, and
trimethoprim), Hoffman-LaRoche Inc., Nutley, N.J. (sul-
fadoxine), the Division ofExperimental Therapeutics, Walter
Reed Army Institute of Research, Washington, D.C.
(dapsone, sulfalene, and cycloguanil), and the Sigma Chem-
ical Co., St. Louis, Mo. (PABA and FA). Methods for the
quantitative assessment of antimalarial activity in vitro were
based on a semiautomated microdilution technique de-
scribed previously (4). With inhibition of uptake of [G-
3H]hypoxanthine as an index of response at each concentra-
tion of drug, concentration-response curves were generated
by fitting the data to a newly derived logistic-logarithmic
function:
U-L
Yi = L (2)
1 + ( f)( f)
where Yi and Xi are the response and concentration, respec-
tively, of the ith sample, U and L are, respectively, the
upper (minimum effect control) and lower (maximum effect
control) asymptote of the response curve, f is the fractional
response parameter (inhibitory concentration [IC] - f; 0 < f
< 1), and s is a scaling for slope parameter. This form of the
RESULTS
Parasite growth under different medium conditions. All
four of the isolates used in these studies were readily
maintained in continuous culture with normal medium with
normal plasma. Their growth rates (R) varied from an
average of 0.35 for the Liberia I/UNC isolate to 1.2 for the
Indochina I/CDC and Indochina III/CDC isolates. Three of
the isolates, Liberia I/UNC, Indochina I/CDC, and Indo-
china III/CDC, grew equally well simultaneously in -normal
and deficient medium with dialyzed and nondialyzed plasma.
Figure 1 shows the growth of the Liberia IIUNC isolate
under three of these conditions over a period of 28 days.
The Sierra Leone I/CDC isolate did not grow in deficient
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FIG. 1. Growth rates in vitro of Liberia I/UNC isolate of P.
falciparum in normal or deficient medium with normal plasma or
deficient medium with dialyzed plasma. The growth rate (R) is
defined by equation 1 in the text.
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HOURS OF INCUBATION IN MICROTITER PLATES
FIG. 2. Uptake of [G-'H]hypoxanthine by the Liberia I/UNC
isolate of P. falciparum during incubation in vitro for 24, 44, or 68 h
in normal or deficient medium supplemented with normal or dia-
lyzed plasma.
the same culture medium supplemented with normal plasma
when compared with its growth in normal medium. It
appeared, therefore, that while the other three isolates could
survive in an FA- and PABA-free environment, the Sierra
Leone I/CDC isolate could not.
Equivalent growth of the Liberia I/UNC isolate in the four
different culture media was also demonstrated by measuring
the uptake of [G-3H]hypoxanthine during a 68-h incubation
(Fig. 2). Uptake of radiolabeled hypoxanthine has been
demonstrated to be a reliable parameter of parasite growth in
an asynchronous culture (2). The ability of deficient medium
with dialyzed plasma to sustain growth of the Sierra Leone
I/CDC isolate was restored by the addition of FA or PABA
to the culture medium. Growth in this case was also indi-
cated by the uptake of [G-3H]hypoxanthine during a 66-h
incubation (Table 1). At concentrations of 10-9, 10-7, and
10-5 M, PABA was considerably more potent than FA in
this regard.
Antimalarial activities of antifols. Previous studies showed
that the activity of achievable concentrations of pyrimeth-
amine against resistant isolates and sulfonamides against all
isolates of P. falciparum could not be demonstrated in vitro
in normal medium with normal plasma (4). For this reason
deficient medium was used in these studies. The necessity
for dialysis of human plasma for this purpose was demon-
strated by comparing the IC50s of sulfadoxine for the Liberia
I/UNC, Sierra Leone I/CDC, and Indochina III/CDC iso-
TABLE 1. Uptake of [G-3H]hypoxanthine by the Sierra Leone
I/CDC isolate of P. falciparum in deficient medium plus dialyzed
plasma with the addition of FA or PABA'
Mean cpm with the following concn of additive:
Additive Control lo-9 M 1o-7 M iO- M
(none)
FA 2,812 2,680 4,618 13,019
PABA 2,812 5,640 11,651 17,767
a 66-h incubation.
TABLE 2. IC50 of sulfadoxine for three isolates of P. falciparum




Liberia I/UNC 20.70 10.36
Sierra Leone I/CDC 30,457 4.35
Indochina III/CDC ECa 3,206
a EC, Exceeds achievable drug concentrations in vitro.
lates in deficient medium supplemented with dialyzed or
nondialyzed plasma (Table 2).
It was also apparent that an adequate concentration-re-
sponse curve could not be obtained for the sulfonamides
even in the deficient medium with a 24-h duration of drug
exposure before labeling with [G-3H]hypoxanthine. The
maximum drug effect (lower asymptote) was not adequate
under these conditions. Drug exposure times of 24, 40, 48,
and 64 h were compared. The optimum duration was 48 h
followed by an 18-h pulse (Fig. 3).
The assays were, therefore, conducted with deficient
medium with dialyzed plasma and 48 h of drug exposure
followed by an 18-h pulse-labeling with [G-3H]hypoxanthine.
The Liberia I/UNC, Indochina I/CDC, and Indochina
III/CDC cultures were maintained under these conditions.
The Sierra Leone I/CDC isolate was maintained in deficient
medium with nondialyzed plasma for 7 to 10 days and
washed three times in deficient medium in preparation for
the assays. The IC50s of dapsone, sulfalene, sulfamethoxa-
zole, sulfadoxine, pyrimethamine, cycloguanil, and trimeth-
oprim for the four isolates of P. falciparum under these
conditions are shown in Table 3.
Antagonism of antifol activity by FA, PABA, and PABG.
The approximate IC90s of sulfadoxine and pyrimethamine
for the Liberia I/UNC and Indochina I/CDC isolates and of
sulfadoxine for the Sierra Leone I/CDC isolate were ob-
tained from their respective concentration-response curves
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FIG. 3. Concentration-response curves for sulfamethoxazole
against the Indochina III/CDC isolate of P. falciparum with 24-, 40-,
48-, or 64-h drug exposure before labeling with [G-'H]hypoxanthine
for 12 to 18 h. K, x 103.
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TABLE 3. In vitro IC50 of various antifol antimalarial drugs for four isolates of P. falciparum
IC50 (ng/ml) ± SD' for:
Drug Sierra Leone Indochina Indochina
Liberia IIUNC IC1 I/CDC III/CDC
Dapsone 0.057 ± 0.017 1.805 ± 0.890 1,349 ± 489.9 455.0 ± 278.6
Sulfalene 1.140 ± 0.166 0.569 ± 0.235 ECb 2,805 ± 1701
Sulfamethoxazole 0.959 ± 0.608 0.739 ± 0.369 EC 535.5 ± 298.1
Sulfadoxine 10.36 ± 1.76 4.352 ± 3.992 3,671 ± 162.5 3,206 ± 597.1
Pyrimethamine 0.154 ± 0.013 0.117 ± 0.111 63.77 ± 22.96 37.40 ± 10.07
Cycloguanil 0.156 ± 0.063 0.125 ± 0.073 2.718 ± 0.416 2.370 ± 0.544
Trimethoprim 27.01 ± 4.020 22.15 ± 13.08 1,897 + 354.2 1,562 ± 679.9
a0n 3.
b EC, Exceeds achievable drug concentrations in vitro.
presence of the approximate IC9os of these drugs showed no
appreciable growth as indicated by lack of uptake of [G-
3H]hypoxanthine. However, in all cases growth was re-
stored by the addition of FA, PABA, or PABO. The addition
of these nutrients to control cultures did not stimulate
growth of the Liberia I/UNC or the Indochina I/CDC iso-
lates or, under the conditions used for assay preparation, of
the Sierra Leone I/CDC isolate. In the case of sulfadoxine,
FA was consistently more effective than PABA as an
antagonist (Fig. 4, 5, and 6). Conversely, pyrimethamine was
more effectively antagonized by PABA than by FA (Fig. 7
and 8). With the Sierra Leone I/CDC isolate, PABG was
markedly less effective than FA and slightly less effective
than PABA as an antagonist of sulfadoxine (Fig. 6).
DISCUSSION
The ability of three of the four isolates used in these
studies to grow well in deficient medium with dialyzed
plasma was somewhat surprising. The ability of the fourth
isolate, Sierra Leone I/CDC, to survive under these condi-
tions was restored by the addition of PABA or, to a lesser
extent, FA to the culture medium (Table 1). These observa-
tions are not consistent with the suggestion that plasmodia,
like most procaryotic organisms, are unable to utilize intact
exogenous FAs (7).
By depleting exogenous sources of FA and PABA as
much as possible from the culture medium and by extending
the period of drug exposure, it was possible to obtain
quantitative reproducible estimates of the antiplasmodial
activity of a sulfone, sulfonamides, and DHFR inhibitors
against P. falciparum in vitro (Table 3). Although there are
apparent differences in the potency of the sulfone-sulfon-
amide drugs, they are highly cross-resistant. It is unlikely,
therefore, that one would prove effective in a given case and
another would not.
The difference in potency between pyrimethamine and
trimethoprim, both inhibitors of DHFR, was readily pre-
dicted by their relative affinities for the plasmodial enzyme
TABLE 4. Approximate IC90 of sulfadoxine and pyrimethamine
for the Liberia I/UNC and Indochina I/CDC isolates and of




Liberia I/UNC 31 (10-7 M) 0.248 (10-9 M)
Indochina I/CDC 310,000 (10-3 M) 248 (10-6 M)
Sierra Leone I/CDC 3,103 (10-5 M)
a Drug concentration shown in parentheses.
(8). Of somewhat greater interest was the relative lack of
cross-resistance between pyrimethamine and cycloguanil,
the latter being the active metabolite of proguanil. This same
observation has been reported for P. berghei in vivo (19) and
anecdotally on a clinical level with regard to prophylaxis
against fal.iparum malaria (23). In fact, it supports the
suggestion that prophylaxis with proguanil is effective in
areas in which prophylaxis with pyrimethamine is not.
The finding that FA as well as PABA effectively antago-
nized the activity of a sulfonamide in vitro against P.
falciparum was also somewhat surprising, although the same
observation had been reported with P. knowlesi (15) and
more recently with P. falciparum (3). It has been suggested
that this effect is attributable to deco,mposition of the FA or
to contamination with PABG or PABA (7). However, the
FA used in these experiments showed no detectable levels of
PABA in a sensitive microbiologic assay (limit, 0.04 ng/ml,
10-9 M). Furthermore, the fact that PABA and PABG were
considerably less potent than FA as antagonists of sul-
fadoxine (Fig. 6) indicates that the intact molecule rather
than a decomposition product is responsible for this obser-
vation.
In addition to providing a method for the quantitative
assessment of antifol antimalarial activity in vitro, these
studies raise serious doubts about previous assumptions
concerning the FA metabolism of plasmodia. The growth
rate and antagonism experiments suggest, but do not prove,
30K
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FIG. 4. Antagonism of the activity of sulfadoxine (31 ng/ml, 10-'
M) in vitro against the Liberia I/UNC isolate of P. falciparum by FA
and PABA. K, x 103.
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FIG. 5. Antagonism of the activity of sulfadoxine (310 ng/ml,
lo-3 M) in vitro against the Indochina I/CDC isolate of P. falciparum
by FA and PABA. K, x103.
that at least some isolates of P. falciparum under some
conditions are capable of utilizing intact exogenous FAs.
However, many important questions remain to be answered.
A potentially rich source of exogenous FAs not yet
considered is the erythrocyte storage pool of polyglutamated
5N-methyltetrahydrofolic acid (24). It is somewhat remark-
able that plasmodia reside in such an FA-rich environment
and yet are thought to be dependent entirely on de novo
synthesis for their requirements. Utilization of this source of
preformed active FA cofactor would require the elaboration
of a conjugase enzyme capable of hydrolyzing the polyglu-
tamate side chain (13), an activity which has not been
investigated in P. falciparum. The ability to produce such an
enzyme combined with the ability to utilize intact exogenous
FAs would make the parasite substantially capable of resist-
ing the activity of antifol antimalarial drugs. Based on these
findings, it is suggested that resistance of P. falciparum to
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FIG. 6. Antagonism of the activity of sulfadoxine (3,103 ng/ml,
lo-5 M) in vitro against the Sierra Leone I/CDC isolate of P.
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FIG. 7. Antagonism of the activity of pynmethamine (0.248
ng/ml, 10-9 M) in vitro against the Liberia I/UNC isolate of P.
falciparum by FA and PABA. K, x 103.
involve the ability to generate a structurally modified DHFR
(6), overproduction ofDHFR (12), enhanced ability to utilize
intact exogenous FAs, or the ability to cleave the polyglu-
tamate moiety from the abundant erythrocyte-FA storage
pool. It is of interest to note that in these studies and in the
literature an isolate ofP. falciparum which is resistant to one
category of antifol antimalarial drug and sensitive to the
other has not yet been identified, suggesting shared or linked
mechanisms of resistance. The Sierra Leone I/CDC isolate is
noteworthy in this regard because it is highly sensitive to
pyrimethamine in vitro under all conditions (Table 3) and
relatively resistant to sulfadoxine in the presence of even
low concentrations of FA (Table 2).
In a controlled clinical evaluation of the efficacy of a
sulfonamide plus a DHFR inhibitor in nonimmune human
volunteers infected with falciparum malaria, it was sug-
gested that host factors other than drug metabolism played a
role in the therapeutic response (22). The present investiga-
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FIG. 8. Antagonism of the activity of pyrimethamine (248 ng/ml,
10 6 M) in vitro against the Indochina I/CDC isolate of P. falciparum
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tions suggest that the FA status of the host is of importance
in the response of some strains of P. falciparum to these
drugs.
Further exploration of these various potential mechanisms
of resistance to antifol antimalarial drugs should yield results
of considerable practical importance. If, as is suggested by
the present studies, there are multiple potential avenues of
escape for the parasite from chemotherapeutic attack on its
metabolism of FA cofactors, it is unlikely that further
exploration of this approach will provide durable therapeutic
alternatives.
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